FTIR and MS Evidence for Heavy Metal Binding to Anti-amyloidal NAP-Like Peptides

[1]  Sakshi Sachdeva.  Peptides as ‘Drugs’: The Journey so Far , 2016, International Journal of Peptide Research and Therapeutics.

[2]  C. Ciobanu,et al.  Letter: Mass Spectrometric Evidence for Iron Binding to the Neuroprotective Peptide NAP and its Cys5 Mutant , 2016, European journal of mass spectrometry.

[3]  Virander S. Chauhan,et al.  C-Terminal Fragment, Aβ32-37, Analogues Protect Against Aβ Aggregation-Induced Toxicity. , 2016, ACS chemical neuroscience.

[4]  M. Brimble,et al.  Enhancing the Oral Bioavailability of Peptide Drugs by using ChemicalModification and Other Approaches , 2014 .

[5]  Luc Patiny,et al.  ChemCalc: A Building Block for Tomorrow's Chemical Infrastructure , 2013, J. Chem. Inf. Model..

[6]  Marek Luczkowski,et al.  Copper, zinc and iron in neurodegenerative diseases (Alzheimer's, Parkinson's and prion diseases) , 2012 .

[7]  K. Franz,et al.  Minding metals: tailoring multifunctional chelating agents for neurodegenerative disease. , 2010, Dalton transactions.

[8]  I. Gozes,et al.  NAP and D-SAL: neuroprotection against the β amyloid peptide (1–42) , 2008, BMC Neuroscience.

[9]  L. Mucke,et al.  100 Years and Counting: Prospects for Defeating Alzheimer's Disease , 2006, Science.

[10]  D. Blat,et al.  Novel neuroprotective neurotrophic NAP analogs targeting metal toxicity and oxidative stress: potential candidates for the control of neurodegenerative diseases. , 2006, Journal of neural transmission. Supplementum.

[11]  Bruce H. Morimoto,et al.  NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). , 2006, CNS drug reviews.

[12]  M. Willis,et al.  Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. , 2005, American journal of clinical pathology.

[13]  A. Mackinnon,et al.  Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. , 2003, Archives of neurology.

[14]  Claus Jacob,et al.  Metal and redox modulation of cysteine protein function. , 2003, Chemistry & biology.

[15]  H. Sies,et al.  Protein S-Thiolation, S-Nitrosylation, and Irreversible Sulfhydryl Oxidation: Roles in Redox Regulation , 2003 .

[16]  K. Sulik,et al.  Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Ashley I. Bush,et al.  The metallobiology of Alzheimer's disease , 2003, Trends in Neurosciences.

[18]  C. Jacob,et al.  Multiple roles of cysteine in biocatalysis. , 2003, Biochemical and biophysical research communications.

[19]  K. Siu,et al.  A comparison of copper(I) and silver(I) complexes of glycine, diglycine and triglycine , 2001 .

[20]  I. Gozes,et al.  A Novel VIP Responsive Gene: Activity Dependent Neuroprotective Protein , 2000, Annals of the New York Academy of Sciences.

[21]  L. Baratova,et al.  Determination of biologically active low-molecular-mass thiols in human blood. I. Fast qualitative and quantitative, gradient and isocratic reversed-phase high-performance liquid chromatography with photometric and fluorescence detection. , 2000, Journal of chromatography. A.

[22]  A. Barth,et al.  The infrared absorption of amino acid side chains. , 2000, Progress in biophysics and molecular biology.

[23]  Xudong Huang,et al.  The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. , 1999, Biochemistry.

[24]  D. Jacobsen.  Homocysteine and vitamins in cardiovascular disease. , 1998, Clinical chemistry.

[25]  J. D. Robertson,et al.  Copper, iron and zinc in Alzheimer's disease senile plaques , 1998, Journal of the Neurological Sciences.

[26]  P. Haris,et al.  The conformational analysis of peptides using fourier transform IR spectroscopy , 1995, Biopolymers.